Today: 21 July 2026
Aviva share price at 636p: Peel Hunt calls stock a buy as Direct Line Group integration comes back into focus
1 February 2026
1 min read

Aviva share price at 636p: Peel Hunt calls stock a buy as Direct Line Group integration comes back into focus

London, Feb 1, 2026, 09:30 GMT — The market has closed.

  • On Jan. 30, Aviva shares ended the day slightly higher, up 0.13% to 635.8 pence.
  • Peel Hunt kicked off coverage assigning a “buy” rating and set a 755p price target.
  • Investors are eyeing the full-year results on March 5 for updates on buybacks and integration progress.

Peel Hunt kicked off coverage of Aviva on Friday, assigning a “buy” rating and setting a 755 pence target. The broker noted that the insurer’s UK reset is mostly behind it now. They highlighted the integration of Direct Line as the next major trigger, with rollout anticipated by fiscal 2028. Proactiveinvestors NA

Markets are closed Sunday, but this note is crucial before Monday’s open since Aviva has become a key income stock for numerous UK investors. The focus has shifted from “what’s the plan” to “when will the cash return.”

Aviva’s shares ended Jan. 30 at 635.8 pence, edging up 0.13% after fluctuating between 634.6 and 640.4 pence during the session. According to Investing.com data, the stock remains roughly 9% shy of its 52-week peak at 700.6 pence.

Matt Britzman, senior equity analyst at Hargreaves Lansdown, pointed out that the increased synergy targets are significant because unlocking capital should help boost the solvency ratio — a key gauge of regulatory capital strength — following the Direct Line acquisition. He added this could “bring buybacks back into play sooner.” Insurance Business

Aviva gave a November trading update, targeting £225 million in cost synergies and over £0.5 billion in capital synergies from the acquisition. The insurer expects regulatory approval for the capital benefits by late 2026. CEO Amanda Blanc described the integration as “well underway” and confirmed plans to restart share buybacks in 2026. Aviva

But there’s a catch. Peel Hunt flagged that the UK property and casualty (P&C) sector — including motor and home cover — is entering a more challenging phase of the cycle, with claims inflation capable of shifting rapidly. Plus, any significant capital increase hinges on getting the green light from regulators.

Insurers frequently move in step with bond yields, given they funnel premiums into bonds and rely on those rates to set annuity prices. That connection keeps Aviva exposed to shifts in the broader rates market, even when company-specific news is thin.

The broker compared Aviva’s life business with its peers, highlighting its greater diversification compared to Legal & General and Phoenix Group. Workplace pensions and savings play a larger role in Aviva’s mix, the broker noted.

Aviva’s full-year results are set for March 5, with the report dropping at 0700 GMT. The insurer will follow up with an investor update at 0830 GMT.

Traders will be watching for follow-through from Friday’s broker call as London trading picks up again on Feb. 2. The market is then eyeing March 5 for the next clear update on capital returns, integration progress, and any guidance adjustments.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Novartis Tops Q2 Profit Forecasts, Maintains 2026 Targets as R&D Remains in Focus
    July 21, 2026, 11:57 AM EDT. Novartis posted a Q2 core operating profit of $5.94 billion, beating analyst forecasts of $5.31 billion. The Swiss pharmaceutical company reaffirmed its 2026 outlook and full-year growth guidance, noting that one-off gains are expected to normalize as research and launch investment picks up in the second half. Results from key studies on drugs such as pelacarsen and remibrutinib could help offset losses from patent expiries, especially for its heart medication Entresto.
Imperial Brands stock price rises as buyback rolls on — what to watch before Monday open
Previous Story

Imperial Brands stock price rises as buyback rolls on — what to watch before Monday open

Nippon India Silver ETF price today: SILVERBEES slides as silver swings shake bullion ETFs
Next Story

Nippon India Silver ETF price today: SILVERBEES slides as silver swings shake bullion ETFs

Go toTop